Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 8/20 | 0.38 |
| ▸ | WDR48 | Q8TAF3 | 8/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766869 | 0.81 | CYP1A2 (0.39) | ADORA2ACYP1A2GRM5CYP2D6CYP3A4 | |
| SCHEMBL8778593 | 0.79 | LCK (0.36) | USP1WDR48CYP1A2GRM5 | |
| SCHEMBL8779827 | 0.78 | PDGFRB (0.45) | ADORA2ACYP1A2GRM5LMNA | |
| SCHEMBL8870205 | 0.77 | CYP1A2 (0.40) | USP1WDR48CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL8778498 | 0.77 | USP1 (0.34) | USP1WDR48CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL8778539 | 0.75 | GRM5 (0.37) | CYP1A2GRM5LMNA | |
| SCHEMBL8778436 | 0.74 | CYP1A2 (0.37) | ADORA2ACYP1A2GRM5 | |
| SCHEMBL8778633 | 0.74 | GRM5 (0.46) | CYP1A2GRM5GRM4CYP2D6CYP3A4 | |
| SCHEMBL8775329 | 0.73 | USP1 (0.46) | USP1WDR48CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL8778467 | 0.72 | GRM5 (0.37) | CYP1A2GRM5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012069652-A2 | FUNGICIDE MIXTURES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | USP1 2963/4885WDR48 4477/4885ADORA2A 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.